Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study
Oxaliplatin-based HIPEC with secondary CRS might provide a survival benefit for patients with recurrent ovarian cancer with a decreased incidence of renal toxicity compared to cisplatin-based regimens. It might be effective and feasible in selected recurrent ovarian cancer patients, regardless of platinum-sensitive or resistant.
Authors
- Wei‐Ting Chao (ORCID: https://orcid.org/0000-0001-9234-8853)
- Hua-Hsi Wu
- Peng-Hui Wang
- Yi‐Jen Chen (ORCID: https://orcid.org/0000-0001-9281-1940)
Institutions
- Fu Jen Catholic University (TW)
- National Yang Ming Chiao Tung University (TW)
- China Medical University (TW)
- Taipei Veterans General Hospital (TW)
- China Medical University Hospital (TW)
Publication Details
- Journal
- Journal of the Formosan Medical Association
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1016/j.jfma.2024.08.014
- Citations
- 5
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Taipei Veterans General Hospital